Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Compugen Discloses Focused Target Discovery Program for ADC Cancer Therapy

Published: Tuesday, April 09, 2013
Last Updated: Tuesday, April 09, 2013
Bookmark and Share
Initial discoveries from new program anticipated before year-end.

Compugen Ltd. has disclosed the initiation of its second focused discovery program, aimed at identification of novel targets for antibody-drug conjugate (ADC) cancer therapy focusing on clinical situations with poor survival rates and/or recurrent cancers.

This second program follows Compugen's successful initial focused discovery program for novel immune checkpoint proteins, a number of which have been incorporated in the Company's Pipeline Program as Fc fusion protein drugs for immunology and/or as therapeutic targets for monoclonal antibody (mAb) drugs for cancer immunotherapy.

Cancer therapy through ADCs, whereby the antibody delivers a cytotoxic drug directly and specifically to the cancer cell in order to induce direct killing of the cells, addresses an area of high unmet medical need and is of great interest to the pharma industry.

However, the lack of suitable ADC targets is a major problem. This provides an opportunity for Compugen to serve as a key source of such potential targets and their mAbs.

Dr. Anat Cohen-Dayag, president and CEO of Compugen, stated, “Concurrent with our further research and development activities and collaboration discussions involving our leading Pipeline Program product candidates, we are pleased to disclose this second focused discovery effort, which was a previously stated objective for 2013. Based on the success of our first such effort, we expect initial ADC target discoveries to be added to our pipeline by yearend, thus further expanding the scope and diversity of the cancer therapy arm of our pipeline.”

The new discovery platform is designed to provide hypothesis-driven analysis of complex sets of expression and clinical data to predict proteins that can serve as novel mAb targets.

The platform is based on the integration of multiple proprietary systems, tools, and algorithms from Compugen’s existing predictive discovery infrastructure with additional new specialized algorithms and queries geared towards ADC target discovery.

Through the use of this discovery platform, utilizing data from numerous clinically annotated biological samples from various solid cancers, Compugen intends to identify potential high value targets expressed on the surface of various types of cancer cells that are associated with poor clinical outcomes, such as low overall survival and short relapse-free survival.

A planned additional use of the discovery platform is the identification of mAb targets associated with tumors unresponsive to certain treatments, thereby potentially providing a more personalized therapeutic approach based on the target's expression level in individual patients.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Compugen Discloses New Results Supporting CGEN-15052
Data presented at the Inaugural International Cancer Immunotherapy Conference in New York City.
Thursday, September 17, 2015
Compugen Obtains Rights to Use Biological Systems and Materials
Additional capabilities anticipated to enhance research and development of Compugen’s immuno-oncology programs.
Wednesday, April 15, 2015
Compugen Announces Planned Relocation of Headquarters to Larger Facilities
New facilities double available space for corporate offices and research and discovery in Israel.
Wednesday, March 25, 2015
Compugen Expands and Strengthens Business Development Team
Felix Karim, PhD, joins Company as Vice President Corporate & Business Development.
Tuesday, March 10, 2015
Compugen Discloses Initial Experimental Results for Predicted ADC Targets
Pipeline program for oncology to be further expanded and diversified with addition of ADC therapeutic programs to ongoing immuno-oncology programs.
Tuesday, January 06, 2015
Compugen Announces Presentations of Results for CGEN-15001
Data indicating novel mechanism of action for CGEN-15001 in maintaining long-term therapeutic effect presented at International Conference on Immune Tolerance in Amsterdam.
Wednesday, October 01, 2014
Compugen Extends Discovery Capabilities to Additional Immunomodulatory Proteins
Incorporation of algorithms modeling additional biological phenomena leads to predictive discovery of four potential immunomodulatory targets.
Tuesday, July 15, 2014
Compugen Announces Addition of Prof. Drew Pardoll to its SAB
Prof. Pardoll is a world leader in immuno-oncology research and in the development of novel cancer therapeutics.
Wednesday, January 22, 2014
Compugen Discloses Discovery of Five Potential Cancer Targets for ADC Therapy
ADC target discovery is company’s second focused discovery program utilizing its in silico predictive discovery infrastructure.
Thursday, December 12, 2013
Compugen Drug Candidate Demonstrates High Effectiveness in Type I Diabetes Animal Model
Short-term administration of CGEN-15001 shown to provide long-term prevention of disease development.
Friday, October 11, 2013
Compugen Target for Cancer Immunotherapy Shown to Affect Multiple Immune Cell Types
CGEN-15049 immune checkpoint protein expressed on wide variety of cancers.
Thursday, September 26, 2013
Compugen Establishes SAB to Guide Pipeline Program Development
Key opinion leaders to advise Company on research and development involving therapeutic product candidates in the fields of immunology and oncology.
Tuesday, August 27, 2013
Compugen Announces Collaboration and License Agreement with Bayer
Compugen to hold 2nd Quarter Conference Call August 7, 2013.
Tuesday, August 06, 2013
Compugen Reports First Quarter 2013 Financial Results
CEO to update Company status in quarterly conference call.
Monday, April 29, 2013
Compugen Announces Discovery of Two Drug Target Candidates for mAb Cancer Therapy
Targets are expressed in multiple cancers and have a distinct mode of action inhibiting two key immune cell subsets.
Tuesday, March 05, 2013
Scientific News
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
Intestinal Worms Boost Immune System In A Surprising Way
EPFL researchers find that intestinal worm infections cause lymph nodes to produce more immune cells as well as grow in size.
Breast Milk Hormones Impact Bacteria In Infants’ Guts
Intestinal microbiome of children born to obese mothers significantly different from those born to mothers of healthy weight, CU Anschutz researchers find.
Improving Natural Killer Cancer Therapy
Vanderbilt University researchers discover transcription factor critical for NK cell expansion. Findings could lead to increased therapeutic efficacy.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Gut Microbiomes Of Infants Have An Impact On Autoimmunity
Exposure to pathogens early in life is beneficial to the education and development of the human immune system.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
COPD Linked to Increased Bacterial Invasion
Persistent inflammation in COPD may result from a defect in the immune system that allows airway bacteria to invade deeper into the lung.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
Vaccinations Are More Effective When Administered In The Morning
Research from the University of Birmingham shows that influenza vaccinations have more protective responses when administered in the morning.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!